Albany Molecular Research Inc. (AMRI) Sees Large Volume Increase
Albany Molecular Research Inc. (NASDAQ:AMRI) saw unusually-high trading volume on Friday . Approximately 1,167,634 shares traded hands during trading, an increase of 203% from the previous session’s volume of 385,752 shares.The stock last traded at $14.44 and had previously closed at $14.32.
Separately, Morgan Stanley reissued a “buy” rating on shares of Albany Molecular Research in a research note on Sunday, May 8th.
The firm’s market cap is $498.24 million. The company has a 50-day moving average of $13.99 and a 200-day moving average of $14.84.
Albany Molecular Research (NASDAQ:AMRI) last released its earnings results on Tuesday, May 10th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by $0.14. The company had revenue of $102.80 million for the quarter, compared to the consensus estimate of $107.20 million. On average, analysts predict that Albany Molecular Research Inc. will post $1.05 EPS for the current fiscal year.
In related news, Director Kevin Oconnor sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total value of $72,050.00. Following the completion of the sale, the director now directly owns 52,955 shares of the company’s stock, valued at approximately $763,081.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO George Svokos bought 12,500 shares of Albany Molecular Research stock in a transaction that occurred on Friday, May 13th. The stock was purchased at an average cost of $12.82 per share, with a total value of $160,250.00. Following the completion of the acquisition, the chief operating officer now directly owns 108,685 shares in the company, valued at approximately $1,393,341.70. The disclosure for this purchase can be found here.
A hedge fund recently raised its stake in Albany Molecular Research stock. Mutual of America Capital Management LLC boosted its stake in Albany Molecular Research Inc. (NASDAQ:AMRI) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 158,399 shares of the company’s stock after buying an additional 8,689 shares during the period. Mutual of America Capital Management LLC owned approximately 0.46% of Albany Molecular Research worth $3,144,000 as of its most recent filing with the SEC.
Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.